Status:
TERMINATED
Phase III Acute Coronary Syndrome
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Pfizer
Duke Clinical Research Institute
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute co...
Eligibility Criteria
Inclusion
- Acute coronary syndrome (ACS)
- Clinically stable
- Receiving standard of care for ACS
Exclusion
- Severe hypertension
- Active bleeding or high risk for major bleeding
- Hemoglobin \< 9 g/dL
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
7484 Patients enrolled
Trial Details
Trial ID
NCT00831441
Start Date
March 1 2009
End Date
March 1 2011
Last Update
January 27 2016
Active Locations (1012)
Enter a location and click search to find clinical trials sorted by distance.
1
Uab Medical Center
Birmingham, Alabama, United States, 35294
2
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35294
3
Heart Center Research, Llc
Huntsville, Alabama, United States, 35801
4
North Phoenix Heart Center
Phoenix, Arizona, United States, 85020